首页> 外文期刊>Chemotherapy: International Journal of Experimental and Clinical Chemotherapy >Treatment and implications of multidrug-resistant tuberculosis for the 21st century.
【24h】

Treatment and implications of multidrug-resistant tuberculosis for the 21st century.

机译:21世纪耐多药结核病的治疗和意义。

获取原文
获取原文并翻译 | 示例
           

摘要

Drug-resistant tuberculosis fundamentally reflects inadequate chemotherapy. To prevent increases in the prevalence of resistance, physician education and more structured treatment programs are needed. In one recent series, 80% of patients with multidrug-resistant tuberculosis (MDR-TB) had been previously managed with clear breaches of standard practice. These errors included adding a single drug to a failing regimen, failing to identify initial or acquired resistance, using an inadequate regimen, and not recognizing (and coping with) non-adherence to therapy. Both medical and surgical management should be considered in optimizing treatment of patients with MDR-TB. Optimal treatment strategies for MDR-TB are outlined in this paper. The use of susceptibility testing is strongly advised, but in situations where such laboratory services are not available, empirical management regimens are discussed.
机译:耐药结核病从根本上反映了化疗不足。为了防止耐药性患病率增加,需要对医生进行培训并制定更有条理的治疗方案。在最近的一系列研究中,以前对80%的耐多药结核病(MDR-TB)患者进行了明显违反标准操作的治疗。这些错误包括在失败的治疗方案中添加单一药物,使用不正确的治疗方案未能识别出最初或获得的耐药性,无法识别(并应对)对治疗的不依从性。在优化耐多药结核病患者的治疗时,应同时考虑药物和手术管理。本文概述了耐多药结核病的最佳治疗策略。强烈建议使用药敏试验,但是在没有此类实验室服务的情况下,将讨论经验管理方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号